Neurological disorders can be some of the most difficult conditions to treat because they often involve damage to the brain, spinal cord, or nerve cells. Conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson’s disease, spinal cord injury, traumatic brain injury, and Alzheimer’s disease can significantly affect mobility, memory, muscle control, independence, and overall quality of life.
Because the nervous system has a limited ability to repair itself after injury or disease, researchers continue to explore regenerative medicine approaches that may help support healing, reduce inflammation, and protect nerve tissue. One area of growing interest is mesenchymal stem cell-based therapy. In this systematic review published in Frontiers in Medicine, researchers examined clinical studies using mesenchymal stem cells (MSCs) for several well-studied neurological conditions.
Why Researchers Are Studying MSCs for Neurological Conditions
Mesenchymal stem cells are being studied in regenerative medicine because of their ability to support tissue repair, regulate immune activity, and release signaling molecules that may influence healing. In neurological conditions, researchers are especially interested in MSCs because they may help create a more supportive environment for damaged nerve tissue.
According to the review, MSCs may migrate toward damaged neural tissue, release helpful biological factors, support neurogenesis, and influence repair-related pathways. These properties make them an important area of study for conditions where inflammation, degeneration, and tissue damage occur together.
The authors also noted that MSCs can come from several sources, including bone marrow, umbilical cord, placenta, peripheral blood, and other tissues. According to the studies included in the review, researchers examined different MSC sources and delivery methods, including intravenous infusion, intrathecal administration, lumbar puncture, and direct injection depending on the condition being studied.
Study Overview
This review followed PRISMA guidelines and focused on published clinical trials involving MSC therapy for neurological disorders. Researchers searched PubMed and selected studies that included information on MSC treatment, clinical outcomes, and safety observations. The final review included 43 clinical studies involving conditions such as ALS, MS, Parkinson’s disease, spinal cord injury, traumatic brain injury, and Alzheimer’s disease.
The selected studies varied in design, treatment method, MSC source, route of administration, and follow-up time. Some studies followed patients for several months, while others included longer follow-up periods. The review focused on two main areas: how well patients tolerated MSC therapy and whether clinical measurements showed signs of improvement after treatment.
Key Findings From the Review
Overall, the authors found that MSC-based therapies were generally reported as safe and tolerable in many of the selected studies. Some commonly reported side effects included low-grade fever, headache, back pain, nausea, or discomfort at the injection site. In several studies, these effects were described as mild and temporary.
The review also found encouraging clinical trends across several neurological conditions. Some studies reported improvements in patient function, neurological scores, mobility, or disease-specific assessment measures. While the level of improvement varied between conditions and study designs, the review highlights the growing body of clinical research supporting continued investigation into MSC therapy for neurological disorders.
For spinal cord injury, several studies reported improvements in neurological function, sensory or motor scores, urodynamic measures, or voluntary muscle contraction in certain patients. One study involving umbilical cord-derived MSCs for thoracolumbar spinal cord injury reported advantages in neurofunctional recovery compared with rehabilitation therapy and control groups.
For multiple sclerosis, the review included studies involving different MSC sources, including umbilical cord-derived MSCs, placenta-derived cells, and MSC-derived neural progenitors. These studies reflect the continued interest in MSC-based approaches for immune regulation and neurological support in progressive or difficult-to-treat forms of MS.
How MSCs May Support Neurological Repair
One of the major reasons MSCs are being studied for neurological disorders is that they may influence several biological processes at once. Instead of targeting only one pathway, MSCs may help regulate inflammation, support cell survival, release growth factors, and encourage repair-related signaling.
This broad activity is important because neurological disorders are often complex. For example, ALS involves motor neuron degeneration, MS involves immune-mediated damage to myelin and nerve fibers, and spinal cord injury involves inflammation, tissue disruption, and impaired nerve signaling. MSC-based therapies may be useful because they are being studied for their ability to interact with several of these processes simultaneously.
The review also highlights the importance of administration route. Depending on the condition, researchers used different delivery methods to help MSCs reach or influence the affected area. This includes intrathecal delivery, intravenous infusion, lumbar puncture, and direct application near injury sites. These different methods are part of ongoing research into how MSC therapy may be optimized for neurological conditions.
A Growing Area of Regenerative Medicine Research
This systematic review shows that mesenchymal stem cell-based therapy remains an active and expanding area of neurological research. Across the 43 clinical studies reviewed, MSCs were investigated for a wide range of conditions, including ALS, MS, spinal cord injury, traumatic brain injury, Parkinson’s disease, and Alzheimer’s disease.
While study sizes, methods, and outcomes varied, the overall findings support continued research into MSC therapy as a promising regenerative medicine approach. The authors concluded that MSC transplantation has shown safety and tolerability in selected studies and patient groups, along with several reported therapeutic benefits during follow-up.
As the field continues to develop, future studies may help researchers better understand which neurological conditions respond best, which MSC sources are most effective, and which delivery methods produce the strongest outcomes. For now, this review adds to the growing scientific foundation supporting MSC-based therapies as an important area of regenerative medicine research for neurological diseases.
Source Patel GD, Liu L, Li A, Yang YH, Shen CC, Brand-Saberi B, Yang X. Mesenchymal stem cell-based therapies for treating well-studied neurological disorders: a systematic review. Front Med. 2024 Mar 27;11:1361723. doi: 10.3389/fmed.2024.1361723. Available from: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1361723/full
Related Treatment Pages